SpringerLink
Log in

Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

With the aging society, the number of very-elderly (VE) patients with acute decompensated heart failure (ADHF) is increasing. Although tolvaptan is recommended for patients with ADHF in whom conventional diuretic therapy is ineffective, few reports exist on VE patients over 90 years of age. Therefore, we aimed to evaluate the clinical effectiveness and adverse events associated with tolvaptan in VE patients with ADHF. From January 2011 to December 2018, we retrospectively studied 180 patients with ADHF who were first administered tolvaptan during hospitalization. Patients were divided into two groups, namely, VE patients who were ≥ 90 years of age (n = 32) and not-VE patients (NVE) who were < 90 years of age (n = 148). The primary effective endpoints were the total urine volume and change in body weight. The safety endpoints evaluated were the incidence of hypernatremia (≥ 150 mEq/L) and worsening renal function (WRF) at any time during hospitalization. The median [interquartile range] patient age was 93 [91–94] years in the VE group and 80 [69–85] years in the NVE group. The mean dose of tolvaptan for the first week of administration was similar between groups (7.9 ± 5.0 mg, VE group; 7.3 ± 3.7 mg, NVE group; p = 0.52). There were no significant differences between the two groups in the total urine volume at 24 h (1901 ± 666 mL, VE group; 2101 ± 1167 mL, NVE group; p = 0.33) and that at 48 h (3707 ± 1274 mL, VE group; 4195 ± 1990 mL, NVE group; p = 0.19) and in the mean change in body weight (− 2.5 ± 2.0 kg, VE group; -2.7 ± 2.4 kg, NVE group; p = 0.70). The median duration of hospitalization was 24 [20–9] and 31 [20–42] days in the VE and NVE groups, respectively (p = 0.67). The incidence of hypernatremia (6.3% (2/32), VE group; 3.4% (5/148), NVE group; p = 0.61) and WRF (25.0% (8/32) VE group; 19.6% (29/148), NVE group; p = 0.31) was similar between the groups. In conclusion, tolvaptan has similar clinical effectiveness in increasing urine volume and decreasing body weight, without increased adverse events, in VE patients with ADHF who were ≥ 90 years of age compared to NVE patients with ADHF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mizuno M, Kajimoto K, Sato N, Yumino D, Minami Y, Murai K, Munakata R, Asai K, Keida T, Sakata Y, Hagiwara N, Takano T, Investigators ATTEND (2016) Clinical profile, management, and mortality in very-elderly patients hospitalized with acute decompensated heart failure: An analysis from the ATTEND registry. Eur J Intern Med 27:80–85

    Article  Google Scholar 

  2. Herrero-Puente P, Martín-Sánchez FJ, Fernández-Fernández M, Jacob J, Llorens P, Miró Ò, Alvarez AB, Pérez-Durá MJ, Alonso H, Garrido M, Representing the members of the ICA-SEMES group (2012) Differential clinical characteristics and outcome predictors of acute heart failure in elderly patients. Int J Cardiol 155:81–86

    Article  Google Scholar 

  3. Mogensen UM, Ersbøll M, Andersen M, Andersson C, Hassager C, Torp-Pedersen C, Gustafsson F, Køber L (2011) Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail 13:1216–1223

    Article  Google Scholar 

  4. Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS (2010) Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 160:264–271

    Article  CAS  Google Scholar 

  5. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 297:1332–1343

    Article  Google Scholar 

  6. Tamaki S, Sato Y, Yamada T, Morita T, Furukawa Y, Iwasaki Y, Kawasaki M, Kikuchi A, Kondo T, Ozaki T, Seo M, Ikeda I, Fukuhara E, Abe M, Nakamura J, Fukunami M (2017) Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction: Prospective randomized controlled study. Circ J 81:740–747

    Article  CAS  Google Scholar 

  7. Matsue Y, Suzuki M, Nagahori W, Yoshida K, Onishi Y, Satoh Y, Ono Y, Nishioka T, Noda M, Sugi K, Torii S, Tejima T, Sakurada H, Yamaguchi S, Okishige K, Fujii H, Atsushi Takahashi A (2014) Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE Study. Cardiovasc Drugs Ther 28:73–77

    Article  CAS  Google Scholar 

  8. McKee PA, Castelli WP, McNamara PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441–1446

    Article  CAS  Google Scholar 

  9. Klaeboe LG, Edvardsen T (2019) Echocardiographic assessment of left ventricular systolic function. J Echocardiogr 17:10–16

    Article  Google Scholar 

  10. Hutcheon DE, Mehta D, Romano A (1965) Diuretic action of furosemide. Arch Intern Med 115:542–546

    Article  CAS  Google Scholar 

  11. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN (1985) Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med 103:1–6

    Article  CAS  Google Scholar 

  12. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT (2002) BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circ 105:1348–1353

    Article  CAS  Google Scholar 

  13. Kinoshita M, Okayama H, Kosaki T, Hosokawa S, Kawamura G, Shigematsu T, Takahashi T, Kawada Y, Hiasa G, Yamada T, Matsuoka H, Kazatani Y (2018) Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure. Heart Vessels 33:163–169

    Article  Google Scholar 

  14. Matsukawa R, Kubota T, Okabe M, Yamamoto Y, Meno H (2018) Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure. Heart Vessels 33:145–154

    Article  Google Scholar 

  15. Sato Y, Uzui H, Mukai M, Shiomi Y, Hasegawa K, Ikeda H, Tama N, Fukuoka Y, Morishita T, Ishida K, Kaseno K, Miyazaki S, Nakano A, Tada H (2019) Efficacy and safety of tolvaptan in patients more than 90 years old with acute heart failure. J Cardiovasc Pharmacol Ther 25:47–56

    Article  Google Scholar 

  16. Kiuchi S, Hisatake S, Kabuki T, Oka T, Dobashi S, Fujii T, Ikeda T (2018) The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients. Heart Vessels 33:367–373

    Article  Google Scholar 

  17. Darmon M, Timsit JF, Francais A, Nguile-Makao M, Adrie C, Cohen Y, Garrouste-Orgeas M, Goldgran-Toledano D, Dumenil AS, Jamali S, Cheval C, Allaouchiche B, Souweine B, Azoulay E (2010) Association between hypernatraemia acquired in the ICU and mortality: a cohort study. Nephrol Dial Transplant 25:2510–2515

    Article  CAS  Google Scholar 

  18. Funk GC, Lindner G, Druml W, Metnitz B, Schwarz C, Bauer P, Metnitz PG (2010) Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med 36:304–311

    Article  Google Scholar 

  19. Kinugawa K, Sato N, Inomata T, Yasuda M, Shimakawa T, Fukuta Y (2019) Real-world effectiveness and tolerability of tolvaptan in patients with heart failure: final results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study. Circ J 83:1520–1527

    Article  CAS  Google Scholar 

  20. Kinugawa K, Sato N, Inomata T, Yasuda M, Shibasaki Y, Shimakawa T (2018) Novel risk score efficiently prevents tolvaptan-induced hypernatremic events in patients with heart failure. Circ J 82:1344–1350

    Article  CAS  Google Scholar 

  21. Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Verdiani V, Tijssen JG, Pinto YM (2014) Competing risk of cardiac status and renal function during hospitalization for acute decompensated heart failure. JACC Heart Fail 3:751–761

    Article  Google Scholar 

  22. Carubelli V, Cotter G, Davison B, Gishe J, Senger S, Bonadei I, Gorga E, Lazzarini V, Lombardi C, Metra M (2016) In-hospital worsening heart failure in patients admitted for acute heart failure. Int J Cardiol 225:353–361

    Article  Google Scholar 

  23. Matsue Y, Suzuki M, Toriji S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR (2016) Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 22:423–432

    Article  CAS  Google Scholar 

  24. Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U (2016) Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 67:399–405

    Article  Google Scholar 

  25. Logeart D, Tabet JY, Hittinger L, Thabut G, Jourdain P, Maison P, Tartiere JM, Solal AC (2008) Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 127:228–232

    Article  Google Scholar 

  26. Niikura H, Iijima R, Anzai H, Kogame N, Fukui R, Takenaka H, Kobayashi N (2017) Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure. Anatol J Cardiol 18:206–212

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

None.

Funding

This study was supported by scholarship funds received from Otsuka Pharmaceutical Co., Ltd.

Author information

Authors and Affiliations

  1. Division of Cardiology, Shimane University Faculty of Medicine, Izumo, 693-8501, Japan

    Yusuke Morita, Akihiro Endo, Yuzo Kagawa, Kazuto Yamaguchi, Hirotomo Sato, Takeshi Ouchi, Nobuhide Watanabe & Kazuaki Tanabe

Authors
  1. Yusuke Morita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akihiro Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuzo Kagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuto Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirotomo Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takeshi Ouchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobuhide Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuaki Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yusuke Morita.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Shimane University Institutional Committee on Ethics (July 31, 2020/no. 4752).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morita, Y., Endo, A., Kagawa, Y. et al. Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure. Heart Vessels 36, 836–843 (2021). https://doi.org/10.1007/s00380-020-01753-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-020-01753-3

Keywords

Search

Navigation